Poll

RN Practice Poll #1: Your Strategy After MTX Fails in RA

First in our series of polls about unresolved issues in rheumatology practice: The rheumatoid arthritis patient unhelped by methotrexate monotherapy. What next?

Too many conditions with too many variations. New drug options that arrive too quickly. Too few guidelines to rely on.

On Rheumatology Network, you can help us create an archive of current practice patterns for common conditions not yet addressed by expert consensus or solid evidence-based guidelines. Watch for a new poll every week.

Polls will be updated periodically to monitor changes in practice.

See also:

RN Practice Poll #2:  MTX Plus Anti-TNF Fails in RA: What Next?

 

1. After a patient with rheumatoid arthritis fails methotrexate, I

Add sulfasalazine and hydroxychloroquine (so-called triple therapy)
Add an anti-TNF
Add leflunomide (Arava)
Add abatacept (Orencia)
Add tocilizumab (Actemra)
Add JAK inhibitor tofacitinib (Xeljanz)
Add rituximab (Rituxan)
Related Videos
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and Osteoporosis | Image Credit: Lundquist Institute
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
© 2024 MJH Life Sciences

All rights reserved.